MEK162 for Patients With RAS/RAF/MEK Activated Tumors
NCT01885195
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
110
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor and Hematologic Malignancies
Interventions
DRUG:
MEK162
Sponsor
Pfizer